Estradiol / Drospirenone
Class: Estrogen and progestin combined
- Tablets estradiol 1 mg/drospirenone 0.5 mg
Yasmin 28 (Canada)
Indications and Usage
Treatment of moderate to severe vasomotor symptoms associated with menopause; treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause.
Known or suspected pregnancy; undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasm; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent (eg, within past year) arterial thromboembolic disease (eg, MI, stroke); renal insufficiency; liver dysfunction or disease; adrenal insufficiency; hypersensitivity to any component of the product.
Dosage and AdministrationAdults
PO 1 tablet daily.
Store at 59° to 86°F.
May result in an increase in the pharmacologic and toxicologic effects of corticosteroids.Drugs affecting electrolytes (eg, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, NSAIDs)
Potential increase in serum potassium.Hydantoins (eg, phenytoin)
Possible loss of seizure control.Inducers of CYP3A4 (eg, carbamazepine, modafinil, NNRT inhibitors [eg, nevirapine], phenobarbital, phenytoin, rifampin, St. John's wort)
Estrogen plasma concentrations may be reduced, decreasing the therapeutic effects and changing the uterine bleeding profile.Inhibitors of CYP3A4 (eg, clarithromycin, erythromycin, grapefruit juice, itraconazole, ketoconazole, ritonavir)
Estrogen plasma concentrations may be elevated, increasing the risk of adverse reactions.Thyroid hormones
Serum-free thyroxine concentration may be decreased, increasing the need for thyroid hormone.Topiramate
May reduce estrogen concentration, decreasing the efficacy.
Laboratory Test InteractionsDecreased
Decreased antithrombin III activity; decreased levels of anti-factor Xa and antithrombin III; decreased free hormone concentrations; impaired glucose tolerance; reduced LDL; reduced response to metyrapone test; T 3 resin uptake is decreased.Increased
Increased activated partial thromboplastin time, platelet aggregation time, and PT; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulation activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta thromboglobulin; increased levels of fibrinogen activity; increased plasminogen antigen and activity; increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone; increased corticosteroid binding globulin; increased sex hormone binding globulin; increased angiotensinogen/rennin substrate, alpha-1-antitrypsin, ceruloplasmin; increased TBG and levels of various other lipids and lipoproteins may be affected.
Deep and superficial venous thrombosis; increased BP; MI; pulmonary embolism; stroke; thrombophlebitis.
Headache (10%); changes in libido; chorea; dementia; dizziness; exacerbation of epilepsy; irritability; mental depression; migraine; mood disturbances; nervousness.
Chloasma or melasma; erythema multiforme; erythema nodosum; hemorrhagic eruption; hirsutism; loss of scalp hair; pruritus; rash.
Intolerance to contact lenses; retinal vascular thrombosis.
Abdominal pain (11%); enlarged abdomen (7%); abdominal cramps; bloating; gallbladder disease; nausea; pancreatitis; vomiting.
Breast pain (19%); vaginal hemorrhage (9%); endometrial disorder (2%); leukorrhea (1%); abnormal withdrawal bleeding or flow; breakthrough bleeding; breast cancer; breast enlargement, pain, and tenderness; changes in amount of cervical secretion, cervical ectropion, or vaginal bleeding pattern; dysmenorrhea; endometrial cancer; endometrial hyperplasia; fibrocystic breast changes; galactorrhea; increased size of uterine leiomyomata; nipple discharge; ovarian cancer; spotting; vaginitis, including vaginal candidiasis.
Cholestatic jaundice; enlargement of hepatic hemangiomas.
Peripheral edema (2%).
Hypocalcemia; increased triglycerides; increased weight; reduced carbohydrate tolerance.
Back pain (7%); arthralgia; leg cramps.
Upper respiratory tract infection (19%); sinusitis (5%).
Pain in extremities (8%); decreased weight, flu syndrome (7%); accidental injury (6%); surgery (5%); aggravation of porphyria; anaphylactic/anaphylactoid reactions, including angioedema and urticaria; edema; exacerbation of asthma.
Do not use estrogens for prevention of CV disease or dementia. The Women's Health Initiative study reported increased risks of MI, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during 5 yr of treatment with oral conjugated estrogens combined with medroxyprogesterone. In addition, increased risk of developing probable dementia in postmenopausal women 65 yr of age and older during 5.2 yr of treatment with conjugated estrogens alone and during 4 yr of treatment with oral conjugated estrogens plus medroxyprogesterone was reported. Although the combination of estradiol/drospirenone was not studied, in the absence of comparable data, assume these risks are similar. Because of these risks, prescribe estrogens with or without progestins at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.
Monitor BP at regular intervals; monitor blood glucose levels in patients with diabetes. Consider checking potassium levels during the first treatment cycle in patients predisposed to hyperkalemia.
Category X .
Secreted in breast milk.
Not indicated for use in children.
Drospirenone Cl may be decreased, and estrogens may be poorly metabolized. Use with caution in patients with history of cholestatic jaundice associated with estrogen use or pregnancy.
Special Risk Patients
Use with caution in patients with asthma, diabetes mellitus, epilepsy, hepatic hemangiomas, migraine, porphyria, and systemic lupus erythematosus.
Sustained increases in BP have been attributed to idiosyncratic reactions to estrogens.
Use of unopposed estrogens in women with intact uteri has been associated with increased risk of endometrial cancer, which is related to the dose and duration of estrogen therapy.
May be exacerbated.
Carefully monitor patients with conditions that might be influenced by fluid retention (eg, cardiac or renal dysfunction) because estrogen and estrogen/progestin therapy may cause fluid retention.
The risk of gallbladder disease requiring surgery is increased 2- to 4-fold.
Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases.
Do not use in patients with conditions that predispose them to hyperkalemia (eg, adrenal insufficiency, hepatic or renal function impairment).
In patients with preexisting hypertriglyceridemia, estrogen therapy may be associated with elevations in plasma triglycerides, leading to pancreatitis and other complications.
Use with caution in patients with severe hypocalcemia.
Risk may be increased by drospirenone.
The risk may be increased.
Retinal vascular thrombosis may occur, leading to diplopia, loss of vision, migraine, or sudden onset of proptosis.
Altered potassium and sodium plasma concentrations, nausea, withdrawal bleeding in women.
- Advise patients to discuss the patient information leaflet with the health care provider.
- Advise patients to regularly (eg, every 3 to 6 mo) talk with health care provider to assess the need to continue treatment.
- Advise patients who experience breast lumps, changes in speech, changes in vision, chest pain, dizziness, faintness, leg pain, severe headache, shortness of breath, unusual vaginal bleeding, or vomiting to notify health care provider.
Copyright © 2009 Wolters Kluwer Health.